Purchase this article with an account.
N.A. Sharara, K.R. Van Quill, J.M. O'Brien; The Potential Clinical Utility of Fenretinide in the Treatment of Retinoblastoma: In Vitro Study . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1581.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To investigate the potential clinical utility of the synthetic retinoid, N-(4-hydroxyphenyl)retinamide (fenretinide), in the treatment of retinoblastoma. Methods: Dose-dependent antiproliferative effects of fenretinide were investigated in human retinoblastoma cells in vitro. Established retinoblastoma cell lines, Y79 and Weri-RB1, and primary retinoblastoma cells from patient enucleation specimens were treated with fenretinide at a range of concentrations which spanned clinically observed plasma levels. At a 96 hour endpoint, dose-dependent antiproliferative effects were determined by WST-1 Cell Proliferation Assay (Roche) and Cell Titer-Glo ATP Luminescent Cell Viability Assay (Promega). Assays were performed in triplicate. Results were regarded as positive if the concentration required to induce 50% growth inhibition (IC50) fell within clinically achievable plasma levels. Results: At 96 hours post-treatment, the IC50 of fenretinide was approximately 3µM in Y79 and Weri-RB1 cell lines and 6µM in primary cells from retinoblastoma patients. Results were comparable with both WST-1 Cell Proliferation Assay and Cell Titer-Glo ATP Luminescent Cell Viability Assay. Conclusions: Fenretinide inhibits the proliferation of retinoblastoma cells in vitro at clinically achievable concentrations. This agent has potential efficacy in the treatment of retinoblastoma patients.
This PDF is available to Subscribers Only